November 5, 2008


Pfizer products receive FDA approval to treat foot rot in cattle

Two of Pfizer's products – DRAXXIN Injectable Solution and EXCEDE Sterile Suspension have been approved to treat foot rot in cattle, in addition to treating bovine respiratory disease (BRD).


In addition to treating bovine respiratory disease (BRD), EXCEDE now treats foot rot associated with Fusobacterium necrophorum and Porphyromonas levii. With the advantages of zero milk discard, EXCEDE's extended therapy in a single dose (which works with the immune system of cattle without repeated administration) for BRD and foot rot, helping to save time, labour and stress on cattle.


The use of EXCEDE Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug. Though safe in cattle when properly administered, inadvertent intra-arterial injection in the ear is possible and fatal. EXCEDE has a pre-slaughter withdrawal time of 13 days.


For high-risk beef cattle and dairy calves up to 20 months of age, DRAXXIN is the only anti-infective approved for the treatment of BRD. DRAXXIN works with a cattle's immune system to treat disease without repeated administration, but should not be used for female dairy cattle 20 months of age or older or in calves to be processed for veal. DRAXXIN has a pre-slaughter withdrawal time of 18 days.


Foot rot is a common cause of cattle lameness that can affect just a few animals or 10-15 percent of a herd. High intensity dairy operations have reported foot rot incidence rates up to 25 percent.


Pfizer is a research-based pharmaceutical company that develops animal vaccines and prescription medicines.